Abstract
The present case report describes a case of recurrent and advanced urachal carcinoma including neuroendocrine features with iliac bone metastasis after partial cystectomy and adjuvant chemotherapy consisting of irinotecan and cisplatin in a 32-year-old man. He received gemcitabine/cisplatin/paclitaxel (GCP) combination chemotherapy, consisting of gemcitabin (1,000mg/m2) on day 1, 8, cisplatin (70mg/m2) on day 1, and paclitaxel (80mg/m2) on day 1 and 8. After three cycles of chemotherapy, PET-CT showed complete regression of the disease. So the patient underwent total cystourethrectomy, and histological examination showed an almost complete pathological response. External beam radiation therapy was also given to the ileac bone metastasis regions. However, PET-CT taken 17 months after the external beam radiation showed multiple lung metastases. He received GCP chemotherapy again, which resulted in a complete response again after three cycles of chemotherapy. This is the first report on GCP chemotherapy used not only as a salvage chemotherapy but also as a rechallenge regimen for metastatic urachal cancer including a neuroendocrine component.
| Original language | English |
|---|---|
| Pages (from-to) | 223-227 |
| Number of pages | 5 |
| Journal | Acta medica Okayama |
| Volume | 70 |
| Issue number | 3 |
| Publication status | Published - 2016 |
Keywords
- Cisplatin
- Gemcitabine
- Neuroendocrine component
- Paclitaxel
- Urachal cancer
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
